Skip to main content
. Author manuscript; available in PMC: 2018 Feb 13.
Published in final edited form as: Oncogene. 2017 Aug 7;36(43):6059–6066. doi: 10.1038/onc.2017.264

Figure 2. p110α-deficient ErbB2 tumors remain dependent on PI3K.

Figure 2

(a) Immunoblot of p110αwt/wt/NIC mammary tumor lysates (20μg) from NCr mice injected with (500 000 tumor cells) after treatment with either a vehicle (veh) 125mg/kg of GDC-0941 by oral gavage for the indicated times, (b) Tumor outgrowth in NCr mice injected with tumor cells (500 000 tumor cells) of the indicated genotypes and treated with either vehicle or 125mg/kgof GDC-0941 by oral gavage daily for 6 weeks (c) Difference in tumor growth in between vehicle-treated and GDC-0941-treated tumors after 3 weeks of treatment. The p-values were calculated using a two-tailed Student t-test. (d) Immunoblot of NCr tumor lysates (20μg) from the indicated genotypes.